CORPORATE OFFICERS

Stephen C. Masson
General Manager and Chief Technology Officer

Steve Masson joined InnerPulse in 2003, leading the company's product development, product planning, operations, and early relationships with key technology and funding partners and consultants. He draws from more than 25 years experience in the design and manufacture of implantable medical devices, including pacemakers and defibrillators.

At Ventritex, Inc., Masson served as vice president of product development, overseeing the team that created a series of highly advanced implantable cardiac devices, resulting in the company attaining as much as a 35-percent U.S. market share and more than $125 million in annual revenue. During his more than 10 years at Ventritex, he directed hardware, software, and mechanical development for principal product lines and provided operations and engineering support for products in manufacturing. Previously, he was vice president of research and development at HeartWare, Inc., a cardiac-assist device company, and developed pacemakers at Cordis Corporation.
Back to top.

Earl F. Bardsley
Vice President, Engineering

Earl Bardsley joined InnerPulse in 2009 when he assumed responsibility for product concepts, design, development, analysis and testing for the company's catheter tools used in the implant and explant of Innerpulse's PICDT. His 20+ years experience in medical device R&D and engineering management, specifically with implant products and catheter systems make him a valuable member of the leadership team.

Bardsley's career includes early stage start-up companies as well as Fortune 500 companies. Most recently he held the position of VP R&D at Epitek (Bloomington, MN), an early stage start-up company developing a therapy to prevent stroke. While there he established the R&D strategy to take a novel technology from concept to First-in-Man clinical trials. Other early stage start-up company experience to take products from concept to First-in-Man clinical trials includes: Percardia (Nashua, NH) to develop a catheter based heart bypass procedure and Microvention (Aliso Viejo, CA) to develop stroke prevention products. At Boston Scientific, he managed R&D departments for developing products for radiology, cardiology, and neuroradiology.
Back to top.

Terry Ransbury
Vice President, Research and Development

Terry Ransbury joined InnerPulse in 2003 as its first employee and has played a critical role in developing the company's intellectual property, forging agreements with technology providers, and building the company's technical team. He filed the patents for the platform technology and implantation techniques of the intravascular device.

Ransbury brings 20 years of management and product development experience in the medical device industry to his position, including assignments at early-stage as well as Fortune 500 companies. He was the principal designer of the medical instrumentation device for programming implantable defibrillators at Ventritex, Inc. As clinical manager at BioSense, he oversaw the field introduction of the industry-standard CARTO 3D electrophysiological mapping and ablation system. Each company was acquired for more than $350 million during his tenure. He also co-founded and served as chief technology officer of Resolution Medical, Inc., which developed a high-resolution, body surface mapping system to detect, localize, and quantify arrhythmic and ischemic cardiac events.
Back to top.

Dr. William E. Sanders, Jr.
Vice President of Medical Affairs and Chief Medical Officer
Dr. William E. Sanders, Jr. is a cardiologist who joined InnerPulse in 2007 after 15 years at the University of North Carolina-Chapel Hill as Director of Clinical Cardiac Electrophysiology. He has extensive experience in surgical implantation of defibrillators and pacemakers as well as all aspects of arrhythmia management including ablation. Dr. Sanders has been a major investigator in multiple national clinical trials of implantable medical devices. His publications include articles in the New England Journal of Medicine, Journal of the American College of Cardiology, and Lancet in addition to several book chapters. He is board certified in Internal Medicine, Cardiovascular Disease, and Clinical Cardiac Electrophysiology. He has served as a consultant and advisory board member for several medical companies. Dr. Sanders earned his Medical Degree from the University of North Carolina-Chapel Hill. He trained in cardiology at Baylor College of Medicine and in cardiac electrophysiology at Duke University. He completed a Master of Business Administration at the Kenan-Flagler School of Business, University of North Carolina.
Back to top.

BOARD OF DIRECTORS

William N. Starling, Chairman
Chief Executive Officer, Synecor, LLC

William N. Starling is Chief Executive Officer of Synecor, LLC, (Synecor) a business generator of new Life Science companies based in Research Triangle Park (RTP), North Carolina, Santa Rosa, California, and Portola Valley, California. Synecor (www.synecor.com) has significant academic, scientific, physician, venture capital, corporate, and investment banking partnerships and is focusing its efforts on the identification and development of proprietary, disruptive technologies with extraordinary market potential in the life sciences field.

As CEO of Synecor, Mr. Starling is a cofounder of BaroSense, Inc., Bioerodible Vascular Solutions, Inc., (acquired by Guidant/Abbott in April 2004), InnerPulse, Inc. (formerly Interventional Rhythm Management, Inc.), and TransEnterix, Inc., the initial four companies founded and incubated by Synecor. Mr. Starling currently serves as Chairman of the Board for BaroSense, Inc., a Menlo Park, CA - based obesity company, InnerPulse Inc., a RTP, NC - based cardiac rhythm management company, and CEO of TransEnterix, Inc., a RTP, NC - based less invasive GI Surgery company.

William N. Starling received his BS degree from the University of North Carolina at Chapel Hill and his MBA degree from the University of Southern California. He began his 29 year career in the medical technology device industry at American Edwards Laboratories (Edwards LifeSciences). He was subsequently part of the founding management team and Director of Marketing for Advanced Cardiovascular Systems, Inc. (acquired by Guidant/Abbott), and was a cofounder, Vice President and Board member of Ventritex, Inc. (acquired by St. Jude Medical). In 1992, Mr. Starling was a cofounder and Chairman of the Board of Directors and President/CEO of Cardiac Pathways Corporation (acquired by Boston Scientific Corporation), and was responsible for raising significant capital from the early venture capital period through an initial public offering in 1996.

Mr. Starling has been primarily responsible for raising over $275 million in private and public capital for the companies that he has co-founded and the combined revenues of these companies exceeds $1 billion annually. In addition to the companies that he has co-founded, Mr. Starling has made private investments in the initial equity financings of over 40 startup companies and has served/is a Board member in over 20 early stage life science companies. Mr. Starling also serves as an independent, outside Director of AMI-Semiconductor, Inc. (NASDAQ:AMIS), a key vendor for InnerPulse, Inc.

Mr. Starling serves on the Kenan-Flagler Business School's Board of Visitors at the University of North Carolina at Chapel Hill and the External Advisory Board of the Stanford Stroke Center at the Stanford University Medical Center.
Back to top.

Nathan Every, M.D., Director
General Partner, Frazier Healthcare Ventures

Dr. Nathan Every is a cardiologist who evaluates opportunities in biotechnology and medical devices for Frazier Healthcare Ventures. He joined the firm in 1999, became a partner in 2001, and was instrumental in the formation of incubator Synecor LLC. Previously, he was an associate professor of medicine and the director of the Cardiovascular Outcomes Research Center (CORC) at the University o f Washington.

Every has served on the executive committees of multiple randomized clinical trials in cardiovascular medicine, including the COURAGE trial funded by Merck & Co., Inc., and the OPUS trial funded by Johnson & Johnson. His findings have been published in more than 50 scientific publications, including The New England Journal of Medicine, JAMA, and The Lancet. He serves on national committees for the American College of Cardiology, American Heart Association, and U.S. Department of Veterans Affairs. Board certified in internal medicine and cardiovascular medicine, he earned his medical degree from Emory University and master's degree from the University of Washington's School of Public Health.
Back to top.

V. Kadir Kadhiresan, Ph.D.,  Director
Principal, Venture Investments, Johnson & Johnson Development Corporation

Kadir is a principal at Johnson & Johnson Development Corporation. As part of Medical Device Investment Team he focuses on opportunities throughout the United States.

Kadir has more than 15 years of medical device industry experience in various functional roles including research, product development and business development. Prior to joining JJDC, Kadir was with Guidant Corporation/Boston Scientific, where he led transactions in several novel medical device technologies for joint development, M&A, licensing and monetizing non-strategic assets. Prior to business development, in R&D, Kadir led the development of several early stage technologies by managing more than 60 people and ~$12 MM annual budget. Kadir was also instrumental in the development of the cardiac resynchronization therapy for heart failure, now > $2B market worldwide. At Heart Rhythm Technologies (a subsidiary of Guidant), Kadir led the development of an ablation technology for treatment of atrial fibrillation and raised venture finance for the project.

Kadir is an inventor on more than 25 patents and has published several articles in peer-reviewed journals. Kadir holds a MBA from the Kellogg School of Management at Northwestern University, Evanston, IL. He also graduated with a BS in Electrical Engineering from REC, Trichy, India and MS and PhD in Biomedical Engineering from University of Michigan, Ann Arbor, MI.
Back to top.

John Maroney, Director
General Partner, Delphi Ventures

John Maroney focuses on medical device and diagnostic investments for Delphi Ventures. Before joining the firm in 2003, he was president and chief executive officer of EndoTex Interventional Systems, Inc. He previously held a variety of senior management positions, including president and general manager of EP Technologies, and vice president of operations at both Boston Scientific Corporation and Cardiovascular Imaging Systems (CVIS). While at CVIS, he was a key member of the senior management team during the company's initial public offering and eventual acquisition by Boston Scientific. In addition to his IRM duties, he serves on the board of directors of TriVascular, Inc., and as chairman of the board of EndoTex. He earned a bachelor's degree in mechanical engineering from the University of California, Davis.
Back to top.

John Onopchenko, Director
Synergy Life Science Partners

John Onopchenko is a Managing General Partner of Synergy Life Science Partners, a venture capital fund investing in private, early stage medical device firms or emerging companies who are combining a medical device with a therapeutic payload (drugs, biologics, etc) - so called "combination product" opportunities.

John has spent his entire 25-year career in the medical device industry. He has nearly 20 years of senior leadership experience split equally between two world-class companies: General Electric & Johnson & Johnson. As a venture capitalist, John's experience spans the last 6 years as Johnson & Johnson Development Corporation's (JJDC) lead medical device investor.

Prior JJDC, John progressively increased his operating responsibilities through the development and commercialization of six new-to-the-world technologies: surgical stapling, endoscopic surgery, medical lasers, magnetic resonance imaging / spectroscopy, catheter-based therapies guided by digital fluoroscopy, and H2O2 gas plasma sterilization. His global leadership experience includes general management, business and product development, operations along with marketing and sales management.

John received his Masters in Business from the University of Chicago, Graduate School of Business and completed the Advanced Management Program at Oxford. John received his Bachelors of Science degree from Ursinus College.
Back to top.

Daniel A. Pelak, Director

Dan Pelak has a long history as a senior executive in the medical device industry, compiling a successful track record in growing young companies and corporate operating divisions. Before joining InnerPulse, he was the chief executive officer of Closure Medical Corporation, a global leader in the development and manufacture of biomaterial-based medical adhesives, until its acquisition by Johnson & Johnson in 2005. He began his industry career at Medtronic, Inc., where he spent more than two decades. His executive assignments there included vice president of cardiovascular marketing, as well as vice president and general manager of three operating divisions: Nortech, Cardiac Surgery Technology, and Perfusion Systems.
Back to top.

Thomas Prescott, Director
President and Chief Executive Officer, Align Technologies, Inc.

Before joining Align Technologies in 2002, Thomas Prescott was president and chief executive officer of Cardiac Pathways, Inc., and a consultant to Boston Scientific Corporation after its 2001 acquisition of the company. He previously held various sales, general management, and executive positions with Nellcor Puritan Bennett, Inc., management positions at GE Medical Systems, and sales, marketing, and management positions at Siemens. He also serves as a director of privately held R2 Technologies, Inc. He earned a master's degree from Northwestern University's Kellogg Graduate School of Management and a bachelor's degree in civil engineering from Arizona State University.
Back to top.